Advances in the pharmacologic management of early Parkinson’s Disease.
Hauser, RA, and TA Zesiewicz. 2007. “Advances in the Pharmacologic Management of Early Parkinson’s Disease.”. Neurologist.
Search
Search results
374 results found
The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.
Zesiewicz, TA, L Wecker, KL Sullivan, LR Merlin, and RA Hauser. 2006. “The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated With Levodopa Alone or With Entacapone: Effects of Vitamin Status.”. Clinical Neuropharmacology.
Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington’s disease.
Zesiewicz, TA, KL Sullivan, RA Hauser, and J Sanchez-Ramos. 2006. “Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Chorea in Huntington’s Disease.”. Mov Disord.
Adenosine A2A receptor antagonists for Parkinson’s disease: rationale, therapeutic potential and clinical experience. Drugs Aging. 2005;22:471-482.
Hauser, RA, and MA Schwarzchild. 2005. “Adenosine A2A Receptor Antagonists for Parkinson’s Disease: Rationale, Therapeutic Potential and Clinical Experience. Drugs Aging. 2005;22:471-482.”. Drugs Aging.
Levetiracetam for the treatment of essential tremor. Movement Disorders 2005; 20:640.
Sullivan, KL, RA Hauser, and TA Zesiewicz. 2005. “Levetiracetam for the Treatment of Essential Tremor. Movement Disorders 2005; 20:640.”. Movement Disorders.
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Movement Disorders 2005;20:783-791.
Truong, D, DD Duane, J Jankovic, C Singer, LC Seeberger, CL Comella, MF Lew, et al. 2005. “Efficacy and Safety of Botulinum Type A Toxin (Dysport) in Cervical Dystonia: Results of the First US Randomized, Double-Blind, Placebo-Controlled Study. Movement Disorders 2005;20:783-791.”. Movement Disorders.
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-566.
Group, Parkinson Study. 2004. “A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease. Arch Neurol 2004;61:561-566.”. Arch Neurol.
Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey. Parkinsonism Relat Disord 2004;10:417-420.
Zesiewicz, TA, JA Strom, AR Borenstein, RA Hauser, CR Cimino, H Fontanet, C Cintron, JF Staffetti, PB Dunne, and KL Sullivan. 2004. “Heart Failure in Parkinson’s Disease: Analysis of the United States Medicare Current Beneficiary Survey. Parkinsonism Relat Disord 2004;10:417-420.”. Parkinsonism Relat Disord.
Botulinum toxin A for the treatment of cervical dystonia. Expert Opin Pharmacother 2004;5:2017-2024.
Zesiewicz, TA, W Stamey, KL Sullivan, and RA Hauser. 2004. “Botulinum Toxin A for the Treatment of Cervical Dystonia. Expert Opin Pharmacother 2004;5:2017-2024.”. Expert Opin Pharmcother.
Depression in Parkinson’s disease. Curr Psychiatry Rep 2002;4:69-73.
Zesiewicz, TA, and RA Hauser. 2002. “Depression in Parkinson’s Disease. Curr Psychiatry Rep 2002;4:69-73.”. Curr Psychiatry.